For people with vitiligo and their caregivers
What this page helps you do
Evidence for two separate vitiligo treatments does not automatically support using them together. Learn how to get one clear, coordinated plan before proceeding.
- Your task
- Separate what the evidence supports from what it does not establish for an individual.
- The clinician boundary
- Diagnosis, assessment of activity and body sites, prescribing, monitoring, and personalized treatment decisions belong to a qualified clinician.
If both treatments make sense on their own, can I use them together?
Do not assume so. Evidence for a combination applies to the exact treatments, people, supervision, outcomes, and study design tested. Two options may each be reasonable to discuss. Using them together may remain untested, conflict with a label, create too much burden, or be wrong for you. Evidence Evidence Evidence
What is known
Vitiligo studies test some combinations because the components may affect different parts of the condition or improve a group outcome. Evidence for each component must still be separated from evidence for the exact pair.
What is uncertain
A study of one cream or light device does not show how every similar product will work. This includes creams in the same class as Protopic (tacrolimus). The study may not show which treatment caused a change or whether it lasted.
Does the HI-Light study apply to me?
It may inform a conversation about the exact supervised combination studied. The trial found better group results with home handheld narrowband UVB plus a steroid cream. Still, only a minority met the success goal. Reactions occurred, and benefits did not reliably last after treatment ended. Evidence
What is known
The UK trial studied people with localized active vitiligo. It compared defined groups and included participant-reported treatment success. This is stronger evidence for that exact combination and population than before-and-after images without a comparison group.
What is uncertain
The study does not create a home plan for you. It also leaves gaps about other vitiligo patterns, body areas, ages, skin tones, racial or ethnic groups, countries, creams, devices, and health systems. Its findings still need clinical review and qualified supervision.
What if Protopic (tacrolimus) or Elidel (pimecrolimus) is being combined with light treatment?
Ask both teams to resolve the instructions before you proceed. US labels for tacrolimus and pimecrolimus tell patients to limit or avoid sunlight and ultraviolet treatment. Vitiligo guidelines discuss selected combinations with supervised light therapy. Evidence Evidence Evidence Evidence
What is known
A product label and a clinical guideline serve different purposes. Off-label combination research does not erase the approved warning, and the warning alone does not explain every specialist decision.
What is uncertain
The prescribing and phototherapy teams must decide whether the proposed combination is justified and provide one set of instructions. Evidence for tacrolimus does not automatically apply to pimecrolimus, and one light-treatment setting cannot stand in for another.
Does the current Opzelura label establish using it with narrowband UVB?
No. The current US label defines ruxolitinib cream’s approved use and ultraviolet-exposure precautions; it does not establish the benefit, safety, or instructions for combining it with narrowband UVB. Evidence
What is known
The label is authoritative for the approved indication, warnings, and precautions. It does not turn a separately studied or proposed combination into labeled care.
What is uncertain
Any separate combination study must be reviewed for its exact population, design, outcomes, follow-up, and conflicts with the current label before it can inform a plan.
Who should coordinate my combination plan?
Before proceeding, know what each treatment adds and the evidence for the exact pair. Review label conflicts, major risks, daily effort, and what to track. Confirm which clinician coordinates the plan. Application order, treatment changes, and restart decisions belong there. Evidence Evidence Evidence Evidence Evidence
What is known
Different clinicians or sites of care can give conflicting written instructions. Make sure both teams have the same current medicine list. Ask who will resolve any disagreement so that task does not fall on you.
What is uncertain
Coordination cannot guarantee a result or remove every uncertainty. If the evidence, product label, or written instructions conflict, ask the treating team for clarification instead of improvising.
Evidence and update context
This optional layer shows the evidence boundary reviewed for this page as of 2026-08-03.
- What this evidence supports
- Vitiligo studies test some combinations because the components may affect different parts of the condition or improve a group outcome. Evidence for each component must still be separated from evidence for the exact pair.
- What it does not establish
- A study of one cream or light device does not show how every similar product will work. This includes creams in the same class as Protopic (tacrolimus). The study may not show which treatment caused a change or whether it lasted.
Applicability check
Who was studied?
These fields show what the cited evidence reports about the people and body sites behind outcome or safety claims. “Not reported” means the reviewed source omitted the field; “Pending exact source review” means SteadySkin has not made that determination yet.
It may inform a conversation about the exact supervised combination studied. The trial found better group results with home handheld narrowband UVB plus a steroid cream. Still, only a minority met the success goal. Reactions occurred, and benefits did not reliably last after treatment ended.
- Age range
- Pending exact source review
- Condition subtype
- Pending exact source review
- Severity or extent
- Pending exact source review
- Sample size
- Pending exact source review
- Geography and care setting
- Pending exact source review
- Skin tone or phototype
- Pending exact source review
- Race
- Pending exact source review
- Ethnicity
- Pending exact source review
- Body sites
- Pending exact source review
What that means for this page: This is explicitly gated as a group-level outcome claim, but exact population extraction is still pending. It cannot publish or support an individual prediction until that review is complete.
Ask both teams to resolve the instructions before you proceed. US labels for tacrolimus and pimecrolimus tell patients to limit or avoid sunlight and ultraviolet treatment. Vitiligo guidelines discuss selected combinations with supervised light therapy.
- Age range
- Pending exact source review
- Condition subtype
- Pending exact source review
- Severity or extent
- Pending exact source review
- Sample size
- Pending exact source review
- Geography and care setting
- Pending exact source review
- Skin tone or phototype
- Pending exact source review
- Race
- Pending exact source review
- Ethnicity
- Pending exact source review
- Body sites
- Pending exact source review
What that means for this page: This is explicitly gated as a safety claim, but exact population extraction is still pending. It cannot publish or support an estimate of individual risk until that review is complete.
Evidence behind this page
Sources
Each evidence badge opens the source and its limits. The full list stays available here.
- DailyMed, U.S. National Library of MedicineRegulatory / guideline · not independentRelevant relationship disclosed
- Published
- 2026-01-28
- SteadySkin last checked
- 2026-07-31
What this source can and cannot tell you
Why the independence label says this: The National Library of Medicine hosts DailyMed. The product company submits the label to FDA, so it is authoritative for product labeling but not independent efficacy evidence.
What this source supports
It establishes the US atopic-dermatitis indication, boxed warning, local effects, long-term-use precaution, and ultraviolet instructions for this product.
What it does not support
It does not approve tacrolimus for vitiligo, establish vitiligo efficacy, or resolve off-label guideline discussion of supervised combinations.
Automated draft claim mapping withheld from reader-facing evidence details until clinical or editorial review is recorded. This page is not yet approved for indexing.
- DailyMed, U.S. National Library of MedicineRegulatory / guideline · not independentRelevant relationship disclosed
- Published
- 2026-04-30
- SteadySkin last checked
- 2026-07-31
What this source can and cannot tell you
Why the independence label says this: The National Library of Medicine hosts DailyMed. The product company submits the label to FDA, so it is authoritative for product labeling but not independent efficacy evidence.
What this source supports
Supports the US atopic-dermatitis indication, boxed warning, application-site effects, long-term-use precaution and instructions to avoid ultraviolet treatment and minimize natural or artificial sunlight.
What it does not support
It does not approve pimecrolimus for vitiligo, establish vitiligo efficacy or resolve off-label guideline discussion of supervised combinations.
Automated draft claim mapping withheld from reader-facing evidence details until clinical or editorial review is recorded. This page is not yet approved for indexing.
- U.S. Food and Drug AdministrationRegulatory / guideline · not independentIndependence not established
- Published
- 2025-09-18
- SteadySkin last checked
- 2026-08-06
What this source can and cannot tell you
What this source supports
Supports the defined US nonsegmental-vitiligo indication, limitations of use, boxed warnings, skin-cancer and ultraviolet precautions, and clinical-study labeling.
What it does not support
It does not guarantee benefit, establish suitability beyond the labeled population or authorize adding phototherapy.
Automated draft claim mapping withheld from reader-facing evidence details until clinical or editorial review is recorded. This page is not yet approved for indexing.
- British Journal of Dermatology (Thomas KS, et al.)Clinical research · independentIndependent source
- Published
- 2020-12-28
- SteadySkin last checked
- 2026-07-31
What this source can and cannot tell you
What this source supports
Supports a group-level benefit for the exact supervised topical-corticosteroid and home handheld-light combination studied in active limited vitiligo, alongside minority success, reactions and limited maintenance after treatment ended.
What it does not support
It does not create a general home plan, support other product-device combinations or predict an individual result.
Automated draft claim mapping withheld from reader-facing evidence details until clinical or editorial review is recorded. This page is not yet approved for indexing.
- Journal of the European Academy of Dermatology and VenereologyRegulatory / guideline · not independentRelevant relationship disclosed
- Published
- 2023-09-25
- SteadySkin last checked
- 2026-07-31
What this source can and cannot tell you
Why the independence label says this: The journal is the publisher. This label refers to extensive author relationships disclosed for the recommendation, not to the journal itself.
What this source supports
It supports current expert-consensus terminology, clinical assessment, disease-activity evaluation, treatment-goal discussion, and shared decision-making.
What it does not support
It is not independent comparative proof. It cannot diagnose a reader from a description or photograph.
Automated draft claim mapping withheld from reader-facing evidence details until clinical or editorial review is recorded. This page is not yet approved for indexing.
- British Journal of Dermatology (Eleftheriadou V, et al.)Regulatory / guideline · independentIndependent source
- Published
- 2022-01-01
- SteadySkin last checked
- 2026-07-31
What this source can and cannot tell you
What this source supports
Supports the clinical history and assessment domains, evaluation of associated autoimmune conditions, its recommendation for thyroid function and antithyroid antibody screening, current classification context, treatment-option map, psychosocial assessment, medical photography and the limits of pediatric evidence.
What it does not support
It was designed for UK care and reviewed literature through May 2019; it does not establish a universal testing plan, prescribe an individual plan, or establish current US labeling or coverage.
Automated draft claim mapping withheld from reader-facing evidence details until clinical or editorial review is recorded. This page is not yet approved for indexing.